AAA
VRDN icon

Affinity Asset Advisors’s Viridian Therapeutics VRDN Stock Holding History

Affinity Asset Advisors’s Portfolio VRDN Stock Details VRDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-130,400
Closed -$3.1M – 93
2023
Q2 		$3.1M Buy
130,400
+29,900
+30% +$767K 1.08% 30
2023
Q1 		$2.56M Buy
+100,500
New +$3.22M 0.84% 33

Other funds holding VRDN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Affinity Asset Advisors's VRDN Position: Q2 2026 in Review

Affinity Asset Advisors held its Viridian Therapeutics (VRDN) position steady in Q2 2026 at 250,000 shares worth $4.59M. The position accounts for 0.21% of the portfolio, ranked #81.

Affinity Asset Advisors first reported a position in VRDN in Q1 2022 and has held it in 12 quarters since. The position peaked at $11.9M in Q3 2024. 215 funds tracked by Wall St. Rank hold VRDN as of Q2 2026.

  • Affinity Asset Advisors held 250,000 shares of Viridian Therapeutics worth $4.59M as of Q2 2026.
  • Affinity Asset Advisors left its Viridian Therapeutics share count unchanged in Q2 2026.
  • Viridian Therapeutics made up 0.21% of Affinity Asset Advisors's portfolio in Q2 2026, its #81 holding.
  • Affinity Asset Advisors first reported a position in Viridian Therapeutics in Q1 2022 and has held it in 12 quarters since.
  • Affinity Asset Advisors's Viridian Therapeutics position peaked at $11.9M in Q3 2024.
  • 215 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q2 2026.

Based on Affinity Asset Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.